Tests reduced chemotherapy with an antibody treatment for children with neuroblastoma
Tests whether reduced chemotherapy plus an antibody is safe in children with high-risk neuroblastoma.
Plain-language title generated from the registry record
Registry title: N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma
Key facts
- Where
- New York, United StatesSee the site
- Phase
- Phase 2
Where in United States
- Memorial Sloan-Kettering Cancer CenterNew York, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Memorial Sloan Kettering Cancer Center
- Trial code
- NCT06528496
- Record updated
- 28 August 2026
- Original description
The purpose of this study is to find out whether N10 chemotherapy is a safe and effective treatment for children with high-risk neuroblastoma.Read full original descriptionShow less
N10: Reduced Therapy for High-Risk Neuroblastoma
The purpose of this study is to find out whether N10 chemotherapy is a safe and effective treatment for children with high-risk neuroblastoma.
Inclusion: Diagnosis of NB as defined by histopathology, BM metastases plus high urine catecholamine levels, or positivity in MIBG scan; HR-NB, defined as MYCN-amplified stage L2/M/MS at any age and stage M in patients >18 months old; No more than one prior cycle of HR-NB chemotherapy; Age <19 years; Signed informed consent indicating awareness of the investigational nature of this treatment.
Exclusion: Severe dysfunction of major organs, i.e., renal, cardiac, hepatic, neurologic, pulmonary, hematologic, or gastrointestinal toxicity >/= to grade 3; °Organ dysfunction due to direct effects of primary tumor or metastatic disease, or due to paraneoplastic syndromes associated with neuroblastoma, will not be considered in exclusion criteria. Similarly, complications of interventions to control above direct effects (e.g., steroid- induced hyperglycemia or hypertension) will also not be considered in exclusion criteria; Inability to comply with protocol requirements; Pregnancy.